Newsroom

Wednesday, 12 March 2014

Register for the OrthoSonos Preview at AAOS

 Clinical studies using Bruin Biometrics' OrthoSonos device show promising trends in the detection of early stage osteoarthritis (OA) that could lead to better treatments. OrthoSonos is being revealed to a select group of physicians at an invite-only event during AAOS on March 13th.

"The data is highly encouraging and points to the possibility of a new, evidence-based patient assessment tool being available to Rheumatologists and Orthopedic Surgeons in the near future," said Martin Burns, CEO of Bruin Biometrics. "Early detection of minor and mild-stage OA offers an exciting chance to manage the disease."

Initial data show that patients with confirmed severe OA who are scheduled for arthroplasty demonstrate a consistently negative OrthoSonos Health Index (OHI), while patients with healthy joints have a consistently positive OHI. Patients with OA for whom surgery is not yet required reported OHIs trending from healthy to chronic joints.

Physicians wanting to know more about the March 13th, AAOS event should contact Dr. Herman Lelie (hlelie@bruinbiometrics.com) or Anasheh Shamirian (ashamirian@bruinbiometrics.com).

To learn more, click here.

FaLang translation system by Faboba